KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Vertex Pharmaceuticals (VRTX) over the last 15 years, with Q4 2025 value amounting to $466.0 million.

  • Vertex Pharmaceuticals' Cost of Revenue rose 1006.14% to $466.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 billion, marking a year-over-year increase of 789.28%. This contributed to the annual value of $1.7 billion for FY2025, which is 789.28% up from last year.
  • As of Q4 2025, Vertex Pharmaceuticals' Cost of Revenue stood at $466.0 million, which was up 1006.14% from $414.8 million recorded in Q3 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Cost of Revenue ranged from a high of $466.0 million in Q4 2025 and a low of $192.3 million during Q1 2021
  • Its 5-year average for Cost of Revenue is $321.4 million, with a median of $313.6 million in 2023.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Cost of Revenue skyrocketed by 2989.76% in 2023 and then skyrocketed by 565.46% in 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Cost of Revenue (Quarter) stood at $247.4 million in 2021, then grew by 14.51% to $283.3 million in 2022, then grew by 29.9% to $368.0 million in 2023, then grew by 15.05% to $423.4 million in 2024, then increased by 10.06% to $466.0 million in 2025.
  • Its last three reported values are $466.0 million in Q4 2025, $414.8 million for Q3 2025, and $407.5 million during Q2 2025.